에리불린

에리불린 속성

에리불린 C화학적 특성, 용도, 생산

개요

The U.S. FDA approved eribulin mesylate (also referred to as E7389) in November 2010 for the treatment of metastatic breast cancer (MBC) for patients who previously received at least two chemotherapeutic regimens for late-stage disease. Eribulin is a synthetic analog of the marine natural product halichondrin B, which is isolated from the sea sponge Halichondria okadai. Eribulin retains most of the structural elements that constitute the right hand side of halichondrin B; structure–activity relationship (SAR) studies suggested that the antitumor activity of halichondrin B resides in that part of the molecule . Eribulin is a microtubule inhibitor that binds close to the vinca-binding site of tubulin. Unlike most tubulin inhibitors like taxanes, epothilones, and vinca alkaloids that inhibit microtubule dynamic instability by changing tubulin addition and loss parameters, eribulin’s effects on dynamic instability are novel in that eribulin inhibits the growth phase of microtubules without affecting the shortening phase by binding to microtubule plus ends.

용도

Eribulin is a anticancer drug and also is a fully synthetic macrocyclic ketone analogue of the marine natural product halichondrin B. It derived from a marine sponge (Lissodendoryx sp.) with antineoplastic activity.

정의

ChEBI: Eribulin is a fully synthetic macrocyclic ketone analogue of marine sponge natural products. Inhibits growth phase of microtubules via tubulin-based antimitotic mechanism, which leads to G2/M cell-cycle block, disruption of mitotic spindles, and, ultimately, apoptotic cell death after prolonged mitotic blockage It has a role as an antineoplastic agent and a microtubule-destabilising agent. It is a macrocycle, a polyether, a polycyclic ether, a cyclic ketone, a primary amino compound and a cyclic ketal. It is a conjugate base of an eribulin(1+).

부작용

Eribulin is an anti-cancer drug currently administered intravenously (IV) for the treatment of breast cancer and liposarcoma patients resistant to taxane therapy because of its excellent efficacy against taxane-resistant tumor types. Common side effects of Eribulin include: gastrointestinal reactions (dry mouth, nausea or vomiting, loss of appetite), weakness, pain, chills, cough, convulsions, frequent urination, nasal congestion, irregular heartbeat, difficulty breathing, decreased urine output, frequent urination, headache, etc. Other side effects include fainting, irregular heartbeat, repeated or severe allergic reactions, etc.

Mode of action

Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Eribulin binds to the vinca domain of tubulin and inhibits the polymerization of tubulin and the assembly of microtubules, resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest at G2/M phase, and, potentially, tumor regression.

에리불린 준비 용품 및 원자재

원자재

준비 용품

에리불린 공급 업체

공급자	전화	이메일	국가	제품 수	이점
ChemExpress	+86-19370970350 +86-021-58950125	info@chemexpress.com	China	788	58
ENBRIDGE PHARMTECH CO., LTD.	+8613812269233	tinayang@enbridgepharm.com	China	313	58
Henan Tianfu Chemical Co.,Ltd.	+86-0371-55170693 +86-19937530512	info@tianfuchem.com	China	21620	55
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	33024	60
career henan chemical co	+86-0371-86658258 +8613203830695	sales@coreychem.com	China	29852	58
Shaanxi Yikanglong Biotechnology Co., Ltd.	17791478691	yklbiotech@163.com	CHINA	296	58
Shenzhen Excellent Biotech Co., Ltd.	13480692018	ramyan@ex-biotech.com	CHINA	954	58
Linyi Changqing Chemical Co., LTD	+86-0532-55729510 +8615853232676	marketing@echemi.com	China	322	58
TargetMol Chemicals Inc.	+1-781-999-5354; +17819995354	marketing@targetmol.com	United States	32432	58
Hubei Ipure Biology Co., Ltd	+8613367258412	ada@ipurechemical.com	China	10242	58

에리불린 관련 검색: